2.59

0.00% 0.00

Adverum Biotechnologies Inc (ADVM)

Overview News Price History Option Chain Financials Discussions Forecast

Adverum Biotechnologies Inc stock is traded at $2.59, with a volume of 132.58K. It is up +0.00% in the last 24 hours and down -4.43% over the past month. Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

Previous Close:

$2.59

Open:

$2.53

24h Volume:

132.58K

Relative Volume:

0.41

Market Cap:

$50.56M

Revenue:

Net Income/Loss:

$-94.11M

P/E Ratio:

-0.4309

EPS:

-6.01

Net Cash Flow:

$-86.06M

1W Performance:

+7.02%

1M Performance:

-4.43%

6M Performance:

-54.72%

1Y Performance:

-67.09%

1-Day Range:

$2.53

$2.63

1-Week Range:

$2.475

$3.10

52-Week Range:

$1.78

$10.14

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name

Adverum Biotechnologies Inc

Sector

Healthcare (1170)

Industry

Biotechnology (661)

Phone

(650) 649-1004

Address

100 CARDINAL WAY, REDWOOD CITY, CA

Employee

155

Twitter

@adverumbio

Next Earnings Date

2024-11-07

Latest SEC Filings

ADVM's Discussions on Twitter

Compare ADVM with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ADVM Adverum Biotechnologies Inc	2.59	50.56M	0	-94.11M	-86.06M	-6.01
VRTX Vertex Pharmaceuticals Inc	460.06	113.97B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	521.84	52.15B	14.09B	4.50B	2.96B	39.28
ALNY Alnylam Pharmaceuticals Inc	304.67	40.16B	2.35B	-269.70M	-75.39M	-2.09
ARGX Argen X Se Adr	586.76	35.45B	2.58B	1.06B	-1.28B	16.33
ONC Beone Medicines Ltd Adr	276.53	27.94B	3.81B	-644.79M	-669.77M	-6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-25-24	Initiated	Oppenheimer	Outperform
Apr-30-24	Initiated	H.C. Wainwright	Buy
Jul-07-22	Upgrade	Truist	Hold → Buy
Jul-23-21	Downgrade	Cantor Fitzgerald	Overweight → Neutral
May-03-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Apr-29-21	Downgrade	Chardan Capital Markets	Buy → Neutral
Apr-29-21	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Apr-29-21	Downgrade	Truist	Buy → Hold
Dec-16-20	Initiated	UBS	Neutral
Nov-12-20	Upgrade	Raymond James	Underperform → Mkt Perform
Jun-26-20	Downgrade	Raymond James	Mkt Perform → Underperform
May-13-20	Initiated	RBC Capital Mkts	Outperform
May-05-20	Upgrade	SunTrust	Hold → Buy
Apr-28-20	Initiated	Goldman	Buy
Mar-16-20	Initiated	SVB Leerink	Outperform
Feb-10-20	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Feb-10-20	Upgrade	Chardan Capital Markets	Neutral → Buy
Oct-15-19	Reiterated	Chardan Capital Markets	Neutral
Sep-13-19	Reiterated	Chardan Capital Markets	Neutral
Jun-14-19	Resumed	Raymond James	Mkt Perform
Nov-02-18	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-02-18	Downgrade	SunTrust	Buy → Hold
Sep-21-18	Initiated	Cantor Fitzgerald	Overweight
Aug-30-18	Initiated	SunTrust	Buy
Feb-15-18	Resumed	Piper Jaffray	Overweight
Oct-12-17	Initiated	Raymond James	Outperform

View All

Adverum Biotechnologies Inc Stock (ADVM) Latest News

Jun 06, 2025

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 06, 2025

Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World

Jun 06, 2025

Jun 05, 2025

Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan

Jun 05, 2025

May 16, 2025

Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks

May 16, 2025

May 15, 2025

Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus

May 15, 2025

Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus

May 15, 2025

Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus

May 15, 2025

Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus

May 15, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com

May 15, 2025

Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider

May 15, 2025

May 14, 2025

Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus

May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times

May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph

May 14, 2025

Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan

May 14, 2025

May 07, 2025